A Multicenter, 2-Part, 6-Week, Double-blind, Randomized, Placebo-controlled, Parallel-design Study to Assess the Efficacy and Safety of AEVI-001 in Children and Adolescents (Ages 6-17 Years) With Attention Deficit Hyperactivity Disorder and With or Without Copy Number Variants in Specific Genes Implicated in Glutamatergic Signaling and Neuronal Connectivity

Trial Profile

A Multicenter, 2-Part, 6-Week, Double-blind, Randomized, Placebo-controlled, Parallel-design Study to Assess the Efficacy and Safety of AEVI-001 in Children and Adolescents (Ages 6-17 Years) With Attention Deficit Hyperactivity Disorder and With or Without Copy Number Variants in Specific Genes Implicated in Glutamatergic Signaling and Neuronal Connectivity

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2018

At a glance

  • Drugs Fasoracetam (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Acronyms ASCEND
  • Sponsors Aevi Genomic Medicine
  • Most Recent Events

    • 15 Jun 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Oct 2018.
    • 15 Jun 2018 Planned End Date changed from 1 Feb 2018 to 1 Oct 2018.
    • 12 Jun 2018 According to Aevi Genomic Medicine media release, Top-line results expected during the fourth quarter 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top